How to Decide When to Add Treatment After Psilocybin in TRD
How can clinicians decide when additional depression treatment is needed after a single dose of psilocybin in treatment-resistant depression?
Even when psilocybin produces initial improvement in treatment-resistant depression, many patients later need additional treatment. This study offers a pragmatic way to recognize when to escalate care by using prespecified depressive events and by showing how often new treatment was started by 12 and 52 weeks.
-
Reassess treatment need by 12 weeks
Plan an explicit reassessment of whether further treatment is needed by about 12 weeks after psilocybin administration. Among COMP 001 completers who entered long-term follow-up, 27.3% of the 25 mg group, 47.4% of the 10 mg group, and 58.8% of the 1 mg group had already started a new antidepressant treatment at that point.
-
Use new treatment initiation as a marker of insufficient durability
Interpret the need to start a new antidepressant treatment as evidence that the initial psilocybin benefit was not sufficient to maintain symptom control. In the study, initiation of new antidepressant treatment was itself a prespecified depression-related event and was the most common event reported.
-
Add treatment when depressive worsening reaches study-defined thresholds
Consider additional treatment when depressive symptoms worsen enough to meet the study's event criteria: a MADRS total score increase of 5 or more points from baseline at any postbaseline assessment, or a MADRS total score of 15 or higher plus a 5-point increase across 2 or more consecutive visits. Increased suicidality on MADRS item 10, defined as a score of 5 or 6 or a score of 3 or higher with at least a 2-point increase from baseline, also met criteria for clinically important worsening.
-
Escalate promptly for hospitalization-level or suicidal events
Do not delay additional intervention if the patient is hospitalized because of depression or suicidality, attempts suicide, requires prevention of an imminent suicide attempt, or discontinues because of an MDD-related adverse event or lack of efficacy. These events were prespecified markers of treatment failure or relapse in the follow-up study.
-
Set expectations that many patients will need added treatment within a year
Counsel patients and plan services with the expectation that further treatment is common over 52 weeks. By week 52, new antidepressant treatment had been started in 54.5% of the 25 mg group and 57.9% of the 10 mg group, while the 1 mg group was numerically higher at 76.5%; the 25 mg group tended to initiate later rather than avoid additional treatment altogether.
Clinical Considerations
- The apparent delay in starting new treatment with 25 mg versus 1 mg was descriptive and not formally tested for statistical significance.
- Because many eligible participants did not enroll in the observational follow-up, treatment-initiation patterns may be affected by censoring and selection bias.
- The study allowed newly initiated treatments, including psychotherapies, during follow-up, so treatment changes were not protocol-restricted.
- These data do not establish a full evidence-based stepped-care protocol for post-psilocybin management; they identify when added treatment occurred and what worsening criteria defined a depressive event.
Bottom Line
After psilocybin in treatment-resistant depression, add further treatment when patients meet explicit worsening or suicidality criteria, and reassess by 12 weeks because many patients require additional therapy within months.
